SABCS 2021 Conference Coverage on VuMedi

 

Videos
08:12

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) Followed by AC in High-Risk HER2+ Stage II/III Breast Cancer: Results From the I-SPY 2 TRIAL

FEATURING David Potter
  • 197 views
  • March 23, 2022
18:03

SABCS 2021 Conference Coverage on VuMedi

Final Findings From the CONTROL Trial of Diarrheal Prophylaxis or Neratinib Dose Escalation on Neratinib-Associated Diarrhea and Tolerability in HER2+ EBC

FEATURING Carlos Barcenas
  • 196 views
  • March 21, 2022
11:18

SABCS 2021 Conference Coverage on VuMedi

Oral SERD Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2- mBC Following Progression on Prior ET & CDK4/6i: Results of EMERALD Phase 3 Trial

FEATURING Aditya Bardia
  • 298 views
  • February 4, 2022
  • 2
13:40

SABCS 2021 Conference Coverage on VuMedi

Optimizing Use of HER2 Therapies in MBC

FEATURING Priyanka Sharma
  • 194 views
  • January 25, 2022
08:21

SABCS 2021 Conference Coverage on VuMedi

Examination of Low HER2 Expression in Breast Cancer

FEATURING Aileen Fernandez
  • 132 views
  • January 25, 2022
05:44

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 on CNS Metastases as a Site of First Recurrence in Adjuvant Therapy Trials of HER2+ EBC

FEATURING Nancy Lin
  • 1,201 views
  • January 20, 2022
  • 3
06:59

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on the KEYNOTE-522 Trial of Neoadjuvant Pembro+Chemo vs. Placebo+Chemo Followed by Adjuvant Pembro vs. Placebo in eTNBC: EFS Sensitivity & Subgroup Analyses

FEATURING Peter Schmid
  • 235 views
  • January 17, 2022
  • 1
08:19

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Interim Analysis of the PREDICT Registry: Changes in Treatment Recommendation for a Biologic Signature Predictive of RT Benefit in DCIS

FEATURING Pat Whitworth
  • 272 views
  • January 17, 2022
  • 2
04:20

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 on Sacituzumab Govitecan in mTNBC: Post-Progression Therapy Outcomes in the ASCENT Study Patients

FEATURING Javier Cortes
  • 239 views
  • January 13, 2022
  • 1
10:39

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 KEYNOTE-355 Final Results: Efficacy of Pembro+Chemo vs. Placebo + Chemo for Previously Untreated, Locally Recurrent, Inoperable or mTNBC

FEATURING Javier Cortes
  • 467 views
  • January 13, 2022
09:07

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 on MRI Screening vs. SYMptom-Directed Surveillance for Brain Mets Among Patients With TNBC or HER2+ MBC: SYMPToM Study

FEATURING Katarzyna Jerzak
  • 397 views
  • January 10, 2022
  • 2
07:02

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Updated Results of Tucatinib vs. Placebo Added to Trastuzumab & Capecitabine for Previously Treated HER2+ MBC With Brain Mets: HER2CLIMB Study

FEATURING Nancy Lin
  • 977 views
  • January 10, 2022
  • 6
25:09

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 on Using the Appearance of a Resistance Mutation in Peripheral Blood as the Sole Evidence to Trigger a Change in Systemic Therapy: PADA-1 Study

FEATURING Steven Vogl
  • 479 views
  • January 4, 2022
  • 5
32:47

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

FEATURING Steven Vogl
  • 1,357 views
  • January 4, 2022
  • 11
06:26

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on the Clinical Utility of Genomic Profiling in MBC: Randomized Trial Results

FEATURING Fabricé Andre
  • 338 views
  • January 4, 2022
  • 2
11:25

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 PROs in ECOG-ACRIN EA1131: Platinum vs. Capecitabine in Residual TNBC After Neoadjuvant Chemo

FEATURING Karen Lisa Smith
  • 278 views
  • January 4, 2022
  • 1
14:35

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on QoL Results From OlympiA Trial: Adjuvant Olaparib After (Neo)Adjuvant Chemo in Patients With Germline BRCA1/2 Mutations and High-Risk HER2- EBC

FEATURING Patricia Ganz
  • 290 views
  • December 23, 2021
  • 1
10:48

SABCS 2021 Conference Coverage on VuMedi

Update on T-DXd vs. T-DM1 in HER2+ MBC: Subgroup Analyses From the Phase 3 DESTINY-Breast03 Study

FEATURING Sara A. Hurvitz
  • 904 views
  • December 22, 2021
  • 6
06:17

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021: Does Chemotherapy Benefit Patients With HR+/HER2- ILBC?

FEATURING Marita Yaghi
  • 1,470 views
  • December 22, 2021
  • 4
07:16

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Results of a Prospective Screening Study: Impact of Race and Ethnicity on Incidence and Severity of BC-Related Lymphedema After ALND

FEATURING Andrea Barrio
  • 13 views
  • December 22, 2021
24:23

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Updates on Refining Axillary Management After Neoadjuvant Chemotherapy for EBC: What Does the Evidence Support?

FEATURING Terry Mamounas
  • 801 views
  • December 20, 2021
  • 4
11:50

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on Samuraciclib, a First-in-Class, Oral, Selective Inhibitor of CDK7, in Combination With Fulvestrant in Advanced HR+/HER2- BC

FEATURING Charles Coombes
  • 333 views
  • December 20, 2021
  • 1
13:08

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Updates on Neratinib + Fulvestrant + Trastuzumab for HR+/HER2-Mutant MBC, and Neratinib + Trastuzumab for HER2-Mutant mTNBC: SUMMIT Trial Results

FEATURING Komal Jhaveri
  • 277 views
  • December 20, 2021
  • 3
04:56

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on Ipatasertib + Palbociclib and Fulvestrant in HR+/HER2- Advanced Breast Cancer

FEATURING Mafalda Oliveira
  • 292 views
  • December 16, 2021
  • 1
07:38

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on T-DXd vs.T-DM1 in High-Risk HER2+ Residual Invasive EBC Following Neoadjuvant Therapy: Phase 3 DESTINY-Breast05 Trial

FEATURING Charles Geyer
  • 503 views
  • December 16, 2021
  • 3
04:45

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Presentation on the Detection of ctDNA Post Neoadjuvant Chemotherapy Using a Personalized Assay Associated With Disease Relapse

FEATURING Michail Ignatiadis
  • 401 views
  • December 15, 2021
  • 2
24:21

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on Oligoprogressive Disease in BC: Treating Locally More Than Systemically

FEATURING Amy Xu
  • 505 views
  • December 15, 2021
  • 6
05:24

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Detection of Early Stage BC Recurrence Using a Personalized Liquid Biopsy-Based Sequencing Approach

FEATURING Wolfgang Janni
  • 227 views
  • December 15, 2021
  • 2
06:06

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 MammaPrint and BluePrint Are Prognostic of Outcome Following Neoadjuvant Chemotherapy

FEATURING Alice Chung
  • 324 views
  • December 15, 2021
  • 2
12:37

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on Adjuvant Palbociclib in HR+/HER2- EBC: Final Results From the Phase III PALLAS Trial

FEATURING Michael Gnant
  • 546 views
  • December 15, 2021
  • 1
08:18

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on T-DXd in Patients With HER2+ or HER2-Low-Expressing Advanced Breast Cancer and CNS Involvement: Preliminary Results From the DEBBRAH Phase 2 Study

FEATURING Marta Vaz Batista
  • 325 views
  • December 13, 2021
  • 1
19:53

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on IO and mTNBC: Which Chemo-Backbone and Biomarker Is Best?

FEATURING Rebecca Dent
  • 445 views
  • December 13, 2021
  • 4